Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention

Inclusion Criteria: * Patients with clinical or subclinical ischemic heart disease with indication of percutaneous revascularization. * "De Novo" lesions ≥ 70% * Reference diameters ≥ 2 mm and ≤ 4 mm Accepted participation in the registration with the signing of informed consent Exclusion Criteria: * Cardiogenic shock * Pregnancy * Intolerance or allergy to anti platelet or anticoagulant therapy * Elective surgical procedure scheduled within 6 months after inclusion in the study * Expectancy of life of less than 1 year. * Impossibility of doing 1 year clinical follow-up. * Primary angioplasty in patients with killip class III-IV or mechanical complications. * Patient with pre-procedure restenosis. * Patients who will not be treated all lesions with the Angiolite stent. * Total occlusions * Truncus disease